Please amend the subject application as follows:

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the claims:

1.-26. (Canceled)

27. (Withdrawn) A vaccine comprising allospecific T suppressor cells stimulated by APCs expressing an MHC class I antigen and an MHC class II antigen which T suppressor cells suppress an interaction between CD4+ T helper cells and allogeneic antigen presenting cells (APCs) expressing the same MHC class I antigen and the same MHC class II antigen expressed by the APCs used to stimulate the allospecific T suppressor cells.

28. (Withdrawn) The vaccine of claim 27 wherein the APCs are allogeneic APCs said APCs expressing an MHC class I antigen recognized by the T suppressor cells and an MHC class II antigen recognized by allogeneic CD4+ T helper cells.

29. (Withdrawn) The vaccine of claim 27 wherein the APCs are APCs pulsed with an allopeptide, said allopeptide comprising an amino acid sequence having both MHC class I and MHC class II binding

motifs wherein both motifs are recognized by the stimulated T suppressor cells.

30. (Withdrawn) The vaccine of claim 27 wherein the T suppressor cells are suppressor CD8+CD28- cells.

31. (Withdrawn) A vaccine comprising xenospecific T suppressor cells stimulated by APCs expressing a xenospecific MHC class I antigen and a xenogeneic MHC class II antigen which xenogeneic T suppressor cells suppress an interaction between CD4+ T helper cells and xenogeneic antigen presenting cells (APCs) expressing the same xenogeneic MHC class I antigen and xenogeneic MHC class II antigen expressed by the APCs used to stimulate the xenospecific T suppressor cells.

32. (Withdrawn) The vaccine of claim 31 wherein the T suppressor cells are suppressor CD8+CD28- cells.

33. (Withdrawn) A method of inducing anergic T helper cells which comprises:

a) incubating antigen presenting cells (APC) with allospecific T suppressor cells (Ts);

b) overexpressing in the APC mRNA which encodes at least one monocyte inhibitory receptor (MIR), in a mixture of cells comprising the APCs from step (a), wherein overexpression of MIR transmits negative inhibitory signals to recruit an inhibitory signaling molecule, thyrosine phosphatase SHP-1 such that the APC are rendered tolerogenic; and

c) incubating the APCs from step (b) with T helper cells (Th) to induce Th anergy.

34. (Withdrawn) The method of claim 33, wherein the monocyte inhibitory receptor (MIR) is selected from the group consisting of ILT4 (MIR-10), ILT2 (MIR7), and ILT3.

35. (Withdrawn) The method of claim 33, wherein the Ts are allospecific human suppressor CD8+CD28- T cells.

36. (Withdrawn) The method of claim 33, wherein the Ts are xenospecific human suppressor CD8+CD28- T cells.

37. (Withdrawn) The method of claim 33, wherein the Ts allopeptide are antigen specific human suppressor CD8+CD28- T cells.

38. (Currently Amended) A method of generating a tolerogenic antigen presenting cell (APC) which comprises:

a) contacting an APC with a CD8+CD28- Ts; and

b) causing overexpression, in the APC of step (a), of mRNA which encodes ILT4 (MIR-10), ILT2 (MIR7), or ILT3 ~~an inhibitory monocyte inhibitory receptor (MIR)~~, thereby generating a tolerogenic antigen presenting cell (APC).

39. (Canceled)

40. (Canceled)

41. (Withdrawn) The method of claim 38, wherein the Ts are xenospecific human suppressor CD8+CD28- T cells.

42. (Canceled)

43.-65. (Canceled)

66. (Withdrawn) A method of determining the appearance of T suppressor (Ts) cells which comprises detecting the level of expression of ILT3, ILT4, and ITL2 protein in APCs of a subject, wherein the subject is a xenograft tissue or organ transplant recipient which comprises:

a) obtaining a sample from the subject; and

b) detecting in the sample of step (a) overexpression of mRNA which encodes the ILT3, ITL4, and ILT2 protein in the APC of the subject, wherein detection of overexpression of mRNA which encodes the ILT3, ILT4, and ILT2 protein indicates the appearance of T suppressor cells in the subject.

67. (Withdrawn) The method of claim 66, wherein the Ts are xenospecific human suppressor CD8+CD28- T cells.

68. (Withdrawn) A method of determining the appearance of T suppressor (Ts) cells which comprises detecting the level of expression of ILT3, ILT4, and ILT2 protein in APCs of a subject, wherein the subject is an allograft tissue or organ transplant recipient which comprises:

a) obtaining a sample from the subject; and

b) detecting in the sample of step (a) overexpression of mRNA which encodes the ILT3, ILT4, and ILT2 protein in the APC of the subject, wherein detection of overexpression of mRNA which encodes the ILT3, ILT4, and ILT2 protein indicates the appearance of T suppressor cells in the subject.

69. (Withdrawn) The method of claim 68, wherein the Ts are allospecific human suppressor CD8+CD28- T cells.

70. (Previously Presented) The method of claim 38, wherein the CD8+CD28- Ts cells do not express the BY55 marker.